Pre-Existing Drugs May Restore Sensitivity to Leptin, an Appetite Suppressing Hormone

Yep, it’s two more drugs from the “mouse trials” front but because these drugs are already FDA-approved, researchers think that they will move quickly to human trials.

Jan 22, 2009

Hearts in the medical community beat with considerable excitement at the discovery of leptin in 1994. A hormone produced by fat, leptin has a very useful talent: it tells the brain when to stop eating. So hopes were high that leptin would become the basis of an anti-obesity treatment. What could be simpler than to dose an obese person with a hormone that says, "You're not hungry any more, and you want to stop eating."

Unfortunately, a snag soon emerged. Obese people do not respond to leptin. Scientists faced two mysteries: First, how do people become resistant to leptin in the first place? And second, are there any drugs that increase sensitivity to leptin?

Those questions have remained unanswered for a long time. But a Children's Hospital Boston study, published in the January 7 issue of Cell Metabolism, may have found the answers to both.

First, it appears that a stress-induced condition causes the hypothalamus, the region of the brain that responds to leptin, to resist the hormone.

Second, two drugs (4-PBA and TUDCA), which are already approved by the FDA for use in other medical applications, appear to greatly increase leptin sensitivity. The receptivity of lab mice resistant to the hormone increased as much as 10-fold when the two drugs were used as "chemical chaperones" to prime the mice for leptin injections.

The Boston study found that a condition called "endoplasmic reticulum" stress in the body's peripheral organs leads to leptin resistance. The endoplasmic reticulum (ER) is a cellular component that produces proteins. Other cellular components, called "molecular chaperones," then fold the protein into its ultimate three-dimensional shape and transport it. When the chaperones can't keep up, a stress response is triggered, called "unfolded protein response" (UPR).

The researchers suspected that ER stress and UPR blocked leptin's action in the brain and were at fault for the hypothalamus's leptin resistance. Previous studies had already shown that mice bred to have ER stress were leptin-resistant and tended to obesity. Once the researchers ascertained that such was the case, they turned to an experimental drug therapy that involved using 4-PBA and TUDCA as chemical chaperones.

Currently, 4-PBA (buphenyl) is used to treat cystic fibrosis and urea cycle disorders, while TUDCA (tauroursodeoxycholic acid) is used to treat liver diseases. Both are also being studied for possible treatment of Alzheimer's and Huntington's diseases. Because both drugs are already FDA-approved, the researchers believe that it will be easy to move them quickly to human trials.

A side benefit of the drugs' role as chemical chaperones is that they have also been shown to reduce ER stress in mice with type 2, restoring insulin sensitivity and normalizing blood sugar levels.

Besides being a safe treatment for increasing leptin sensitivity in obese people, the drugs could also enter the rapidly expanding pharmacopeia of diabetes treatment medicines.

Click Here To View Or Post Comments

Categories: Blood Sugar, Diabetes, Diabetes, Insulin, Medications, Medications Research, Professional Issues, Type 2 Issues, Weight Loss

Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12th Annual Product Reference Guide
  • Insulin Syringe Chart
  • Insulin Pen Needles Chart
  • Fast-Acting Glucose
  • Sharps Disposal
  • Blood Glucose Meters Chart
  • Insulin Pumps Chart
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

Top Rated
Print | Email | Share | Comments (0)

You May Also Be Interested In...


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...

Username: Password:
©1991-2015 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.